Induced pluripotent stem cell (iPSC) technology offers the promise of immune-matched cell
therapies for a wide range of diseases and injuries. It is generally assumed that cells derived …

The promise of off-the-shelf cellular therapeutics (CTPs) based on allogeneic induced
pluripotent stem cells (iPSCs) may be hindered by alloimmunity, leading many to suggest …

Reprogramming of antigen-specific T lymphocytes into induced pluripotent stem cells
(iPSCs) and their subsequent re-differentiation has enabled expansion of functional T …

Select subsets of immune effector cells have the greatest propensity to mediate antitumor
responses. However, procuring these subsets is challenging, and cell-based …

Technologies required to generate induced pluripotent stem cells (iPSC) were first
described 15 years ago, providing a strong impetus to the field of regenerative medicine. In …

Mouse and human pluripotent stem cells have been widely used to study the development
of the hematopoietic and immune systems. Although not all cells can be derived with the …

Reprograming somatic cells using exogenetic gene expression represents a
groundbreaking step in regenerative medicine. Induced pluripotent stem cells (iPSCs) are …

Possessing the ability of self‐renewal with immortalization and potential for differentiation
into different cell types, stem cells, particularly embryonic stem cells (ESC), have attracted …

Hematopoietic stem cell-(HSC) and induced pluripotent stem (iPS) cell-derived natural killer
(NK) cells containing engineered functions, such as chimeric antigen receptors (CAR), offer …

The promise of human induced pluripotent stem cells (iPSCs) lies in their ability to serve as
a starting material for autologous, or patient‐specific, stem cell–based therapies. Since the …